Video

Q&A With Robert Giugliano From Brigham and Women's: PCSK9 Inhibitors Provide Hope for Cardiac Patients

Author(s):

It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.

It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.

Robert Giugliano, MD, from Brigham and Women's Hospital discussed the early stages of the medication and what it can mean for treatment of patients going forward during the European Society of Cardiology's annual meeting in London.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.